A case of tooth fracture occurred upon medicating bisphosphonate for an elderly person: Preservation therapy and responses for Stage 0 of bisphosphonate-related osteonecrosis of jaw

ABSTRACT

This case report aimed to report the progress of preservation therapy and response of symptoms and signs for Stage 0 of bisphosphonate-related osteonecrosis of jaw (BRONJ). A 68-year-old female was recognized having a tooth at the left upper first molar fracture upon medicating bisphosphonate (BP) in 2007. At that time, the extraction of the tooth was an absolute contraindication. Therefore, we performed preservation therapy. We observed the symptoms and signs every month. After 5 months, swelling and redness in the entire first molar tooth were seen and fistula formed partly. Bone exposure was not seen. We administrated antibiotics immediately. As a result, symptoms disappeared. On April 10, 2009, the patient visited us as she felt a sense of incongruity in the lower left first and second molar teeth. Clinically, there were no symptoms of pain. However, we observed the radiolucent finding in about 5 mm diameter at apical position by X-ray photography; we considered a possibility of Stage 0 for BRONJ. We immediately administered medicine for 5 days and the symptoms disappeared. At present, no inflammation with signs and symptoms at the upper left first molar and lower left first, second molar parts is shown. We performed preservation therapy for tooth fracture case medicating of BP. Immediate responses for inflammation and symptoms of the Stage 0 of BRONJ have led to success. Hence, dentists should perform regular clinical observation, and enough education to the patient for BRONJ is necessary.

Key words:

Bisphosphonate-Related Osteonecrosis of Jaw - preservation therapy - Stage 0 - tooth fracture

• REFERENCES

• 1 Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003; 61: 1104-7
• 2 Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-7
• 3 Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003; 21: 4253-4
• 4 Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: An emerging oral complication of supportive cancer therapy. Cancer 2005; 104: 83-93
• 5 Magopoulos C, Karakinaris G, Telioudis Z, Vahtsevanos K, Dimitrakopoulos I, Antoniadis K. et al. Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals. Am J Otolaryngol 2007; 28: 158-63
• 6 Carlson ER, Basile JD. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009; 67 (Suppl. 05) 85-95
• 7 Engroff SL, Kim DD. Treating bisphosphonate osteonecrosis of the jaws: Is there a role for resection and vascularized reconstruction?. J Oral Maxillofac Surg 2007; 65: 2374-85
• 8 Takahashi K, Kawabata A, Koike H, Tohnosu N. A case of osteonecrosis of the maxilla associated with the use of a bisphosphonate. Jpn J Oral Maxillofac Surg 2006; 52: 416 [In Japanese with English abstract].
• 9 Iglesias JE, Salum FG, Figueiredo MA, Cherubini K. Important aspects concerning alendronate-related osteonecrosis of the jaws: A literature review. Gerodontology 2015; 32: 169-78
• 10 Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007; 65: 415-23
• 11 Urade M, Tanaka N, Furusawa K, Shimada J, Shibata T, Kirita T. et al. Nationwide survey for bisphosphonate-related osteonecrosis of the jaws in Japan. J Oral Maxillofac Surg 2011; 69: e364-71
• 12 Yoneda T, Oguno H, Sugimoto T, Shibata T, Kinta T, Yamamoto T. et al. Bisphosphonate-related osteonecrosis of the jaw: Position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society of Periodontology, Japanese for Oral and Maxillofacial Radiology and Japanese Society Oral and Maxillofacial Surgeons. J Bone Miner Metab 2010; 28: 365-83
• 13 Mawardi H, Treister N, Richardson P, Anderson K, Munshi N, Faiella RA. et al. Sinus tracts – An early sign of bisphosphonate-associated osteonecrosis of the jaws?. J Oral Maxillofac Surg 2009; 67: 593-601
• 14 Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws – 2009 update. J Oral Maxillofac Surg 2009; 67 (Suppl. 05) 2-12
• 15 Siegel MA, Migliorati CA, Velez I, Forrest M. Exposed bone in the palate. J Am Dent Assoc 2007; 138: 1341-3
• 16 Migliorati CA, Armonis BN, Nicolatou-Galitis O. Oral osteonecrosis associated with the use of ibandronate: Report of a case and clinical implications. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 106: e18-21
• 17 Sarathy AP, Bourgeois Jr. SL, Goodell GG. Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: Two case reports. J Endod 2005; 31: 759-63
• 18 Stanton DC, Balasanian E. Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: Review of 33 surgical cases. J Oral Maxillofac Surg 2009; 67: 943-50
• 19 Williamson RA. Surgical management of bisphosphonate induced osteonecrosis of the jaws. Int J Oral Maxillofac Surg 2010; 39: 251-5
• 20 Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis: An American Academy of Oral Medicine position paper. J Am Dent Assoc 2005; 136: 1658-68
• 21 Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-34
• 22 Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: A long-term complication of bisphosphonate treatment. Lancet Oncol 2006; 7: 508-14
• 23 Palomo L, Bissada N, Liu J. Bisphosphonate therapy for bone loss in patients with osteoporosis and periodontal disease: Clinical perspectives and review of the literature. Quintessence Int 2006; 37: 103-7
• 24 Dodson TB. Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009; 67 (Suppl. 05) 44-52
• 25 Saldanha S, Shenoy VK, Eachampati P, Uppal N. Dental implications of bisphosphonate-related osteonecrosis. Gerodontology 2012; 29: 177-87
• 26 Patel S, Choyee S, Uyanne J, Nguyen AL, Lee P, Sedghizadeh PP. et al. Non-exposed bisphosphonate-related osteonecrosis of the jaw: A critical assessment of current definition, staging, and treatment guidelines. Oral Dis 2012; 18: 625-32
• 27 Hoefert S, Eufinger H. Relevance of a prolonged preoperative antibiotic regime in the treatment of bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg 2011; 69: 362-80